Eisai Buys AkaRx for $255 Million
Eisai Co. Ltd. has acquired AkaRx Inc., a Paramus, N.J.-based drug company focused on thrombocytopenia, for $255 million. AkaRx had raised over $16 million in VC funding, from InterWest Partners, Astellas Venture Capital and Sutter Hill Ventures.
8 January 2010•1 min read
